| Literature DB >> 30519292 |
Stefano Aliberti1, Amy Farr1, Nathalie Tabin1, Francesco Blasi1, Antoni Torres1, Mark Woodhead1, Giovanni Battista Migliori1, Giovanni Sotgiu1, George Dimopoulos1, James D Chalmers1, Felix C Ringshausen1, Michael R Loebinger1, Robert Read1, Gernot Rohde1.
Abstract
ERS has developed a syllabus for postgraduate training in respiratory infections to guide programme designers http://ow.ly/xJ0R30m8CYB.Entities:
Year: 2018 PMID: 30519292 PMCID: PMC6269171 DOI: 10.1183/20734735.026218
Source DB: PubMed Journal: Breathe (Sheff) ISSN: 1810-6838
Figure 1Overview of the Delphi process.
ERS syllabus for postgraduate training in respiratory infections
| 1 Respiratory microbiology | Mandatory |
| 1.1 Normal bacterial flora | |
| 1.2 Classification of respiratory microorganisms | |
| 2 Respiratory bacteria | Mandatory |
| 2.1 Gram positive | |
| 2.2 Gram negative | |
| 2.3 Atypicals | |
| 3 Respiratory viruses | Mandatory |
| 3.1 RNA viruses (seasonal and/or pandemic, emerging) | |
| 3.2 DNA viruses (seasonal and/or pandemic, emerging) | |
| 4 Respiratory fungi | Mandatory |
| 4.1 | |
| 4.2 | |
| 4.3 Pneumocystis | |
| 4.4 Other fungi (including | Optional |
| 5 Mycobacteria | Mandatory |
| 5.1 | |
| 5.2 Non-tuberculous mycobacteria (NTM) | |
| 6 Antimicrobial resistance | Mandatory |
| 6.1 Mechanisms of antibiotic resistance | |
| 6.2 Multidrug-resistant (MDR) bacteria | |
| 6.3 Risk factors for MDR bacteria | |
| 6.4 MDR/extensively drug-resistant (XDR) tuberculosis | |
| 6.5 Risk factors for MDR/XDR tuberculosis | |
| 6.6 NTM resistance | |
| 6.7 Resistance in other microorganisms (anti-fungal and anti-viral resistance) | Optional |
| 6.8 Influenza resistance | Optional |
| 7 Microbiome | Optional |
| 1 Natural barriers | Mandatory |
| 1.1 Cilia/primary ciliary dyskinesia | |
| 2 Innate immune systems | Mandatory |
| 2.1 Complement | |
| 2.2 Cells | |
| 2.3 Defensins | |
| 2.4 Cytokines | |
| 2.5 Inflammation process | |
| 3 Adaptive immune systems | Mandatory |
| 3.1 Humoral immunity | |
| 3.2 Cellular immunity | |
| 4 Immune reconstitution inflammatory syndrome (IRIS) | Optional |
| 5 Pathophysiology of respiratory infections | Mandatory |
| 5.1 Transmission | |
| 5.2 Infection | |
| 5.3 Inflammation | |
| 5.4 Resolution | |
| 1 Epidemiological burden of respiratory infections | Mandatory |
| 1.2 Bacterial infections | |
| 1.3 Viral infections | |
| 1.4 Fungal infections | |
| 1.5 Mycobacterial infections (tuberculosis and NTM) | |
| 2 Risk factors for respiratory infections and transmission | Mandatory |
| 2.1 Environmental risk factors | |
| 2.2 Host risk factors (including other conditions leading to mild immunosuppression, | |
| 2.3 Microbial risk factors | |
| 1 Indication and collection of biological specimens | Mandatory |
| 1.1 Noninvasive (blood, urine, bronchoalveolar lavage, throat swabs) | |
| 1.2 Invasive (sputum, tracheal aspirate, thoracentesis, imaging-guided biopsy, transthoracic fine-needle biopsy) | |
| 2 Microscopy | Optional |
| 3 Culture | Optional |
| 4 Susceptibility testing | Optional |
| 5 Immunological tests | Optional |
| 5.1 Interferon-γ release assay (IGRA) | |
| 5.2 Tuberculin skin test | |
| 5.3 Serology | |
| 6 Molecular testing | Optional |
| 7 Rapid point-of-care diagnostic tests for viral and bacterial respiratory tract infections | Optional |
| 8 Imaging techniques in relation to infections (including chest radiography, computed tomography, lung ultrasounds and magnetic resonance imaging) | Mandatory |
| 1 Antibacterial agents | Mandatory |
| 1.1 Classification and activity (including pharmacokinetics/pharmacodynamics (PK/PD) principles) | |
| 2 Antiviral agents | Mandatory |
| 2.1 Classification and activity (including PK/PD principles) | |
| 3 Antifungal agents | Mandatory |
| 3.1 Classification and activity (including PK/PD principles) | |
| 4 Antimycobacterial agents | Mandatory |
| 4.1 Classification and activity (including PK/PD principles) | |
| 5 Drug delivery or administration | Mandatory |
| 5.1 Oral | |
| 5.2 Inhaled | |
| 5.3 Intravenous | |
| 5.4 Intramuscular | |
| 6 Drug–drug interaction | Mandatory |
| 7 Antimicrobial adverse events | Mandatory |
| 7.1 Haematological side-effects | |
| 7.2 Nausea and vomiting | |
| 7.3 Diarrhoea including | |
| 7.4 Ototoxicity | |
| 7.5 Hepatic toxicity | |
| 7.6 Nephrotoxicity | |
| 7.7 Cardiovascular toxicity | |
| 8 Principles of antimicrobial stewardship (including prevention of infection, infection control, adequate and appropriate treatment) | Mandatory |
| 1 Common upper respiratory tract syndromes (including acute infective rhinitis, sinusitis, pharyngitis, epiglottitis, laryngotracheitis) | Mandatory |
| 2 Acute bronchitis | Mandatory |
| 3 Bronchiolitis | Mandatory |
| 4 Exacerbation of asthma | Mandatory |
| 5 Exacerbation of chronic obstructive pulmonary disease (COPD) | Mandatory |
| 6 Exacerbation of bronchiectasis | Mandatory |
| 7 Community-acquired pneumonia, including nursing-home pneumonia | Mandatory |
| 8 Nosocomial pneumonia, including ventilator-associated pneumonia | Mandatory |
| 9 Aspiration pneumonia | Mandatory |
| 10 Seasonal influenza | Mandatory |
| 11 Extrapulmonary complications | Mandatory |
| 1 Fungal pulmonary infections | Mandatory |
| 2 Lung abscess | Mandatory |
| 3 Nocardiosis | Mandatory |
| 4 Actinomycosis | Mandatory |
| 5 Parasitic pneumonia | Optional |
| 6 Travel born respiratory infections | Mandatory |
| 1 Viruses | Mandatory |
| 1.1 Severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), H1N1, H5N1 | |
| 2 Pandemics | Mandatory |
| 2.1 Identification | |
| 2.2 Management | |
| 2.3 Public health policies | |
| 1 Pulmonary tuberculosis | Mandatory |
| 2 Extrapulmonary tuberculosis | Mandatory |
| 3 Latent tuberculosis infection | Mandatory |
| 4 Nontuberculous mycobacterial infections | Mandatory |
| 1 Asthma | Mandatory |
| 2 COPD | Mandatory |
| 3 Bronchiectasis | Mandatory |
| 4 Adult cystic fibrosis bronchiectasis | Mandatory |
| 1 Neutropenic patients | Mandatory |
| 2 HIV-infected patients | Mandatory |
| 3 Haematological disorders and malignancy | Mandatory |
| 4 Lung and other solid organ transplant recipients | Mandatory |
| 5 Haematopoietic cell transplant recipients | Mandatory |
| 6 Secondary immunodeficiency induced by drugs and biologicals | Mandatory |
| 7 Primary immune deficiency syndromes | Mandatory |
| 1 Parapneumonic effusion and empyema | Mandatory |
| 2 Pleuritis | Mandatory |
| 2.1 tuberculosis, bacterial, | |
| 1 Sepsis, severe sepsis and septic shock | Mandatory |
| 1.1 Virulence factors involved in sepsis | |
| 1.2 Early recognition and management | |
| 1.3 Additional therapies | |
| 1.4 Biomarkers | |
| 1.5 Clinical management | |
| 1 Vaccination | Mandatory |
| 1.1 Influenza vaccination | |
| 1.2 Pneumococcal vaccination | |
| 1.3 Other vaccinations | |
| 2 Other prevention measures | Optional |
| 2.1 Smoking cessation | |
| 2.2 Specific preventive management | |
| 2.3 Prevention of community-acquired pneumonia | |
| 2.4 Dental care | |
| 2.5 Aspiration management | |
| 3 Infection control | Mandatory |
| 3.1 Infection surveillance | |
| 3.2 Universal precautions | |
| 3.3 Isolation and reverse isolation, including specific microbes in cystic fibrosis and bronchiectasis ( | |
| 3.4 Infectious risks to healthcare workers | |
| 3.5 Tuberculosis control and elimination, including Bacillus Calmette–Guérin (BCG) vaccine | |
| 3.6 Immunomodulants (synthetic and microbial) |